Pfizer Recalls Thousands of Levoxyl Thyroid Tablets

The FDA classified the voluntary recall of 15,949 bottles as a Class II action due to potency concerns.

Updated on Oct. 20, 2026 in Heart Disease

Bold flat-color editorial illustration featuring a minimalist amber bottle, representing a systemic pharmaceutical recall action. — Pfizer has recalled nearly 16,000 bottles of Levoxyl thyroid medication after FDA testing found the tablets failed to meet potency requirements. AI Illustration. Upload story photo >

Live Poll

Do you trust that you have sufficient information to identify and replace your potentially recalled medications?

Pfizer initiated a voluntary recall of 15,949 bottles of the thyroid medication Levoxyl on Sept. 29. The FDA later classified the action as a Class II recall on Oct. 16.

Why it matters

The recalled tablets may contain less hormone than prescribed, potentially resulting in ineffective treatment for patients with hypothyroidism. Patients are advised to check their medication packaging for specific lot numbers to ensure it is not part of the recall.

The recall encompasses 15,815 bottles containing 100 tablets and 134 bottles containing 1,000 tablets. Each affected tablet is dosed at 175 micrograms of levothyroxine sodium.

The players

Pfizer

Pfizer is a global pharmaceutical corporation that discovers, develops, and manufactures a wide range of medicines and vaccines.

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.

The details

Testing revealed that the affected tablets failed to meet potency requirements, meaning they do not deliver the intended dosage. The recall impacts products with an expiration date of Nov. 30, 2026, specifically those marked with lot numbers 24W06 and 24W07.

Sept. 29: Pfizer initiated the voluntary recall.
Oct. 16: The FDA classified the recall as Class II.
Nov. 30, 2026: The expiration date of the affected products.

Health Landscape

The FDA Class II recall classification indicates a situation where use of the product may cause temporary or medically reversible adverse health consequences. This action aligns with established federal protocols designed to manage risks when pharmaceutical manufacturing fails to meet quality standards.

Patients should immediately inspect their Levoxyl bottles for lot numbers 24W06 and 24W07 to determine if their medication is affected. Consult with a healthcare provider if you believe your treatment has been ineffective or if you possess the impacted medication.

The takeaway

Maintaining the correct dosage is essential for the effective management of hypothyroidism. If you have concerns about the potency of your medication, verify the lot information and contact your pharmacist for guidance on safe disposal or replacement.